Etelcalcetide
An eight-amino-acid peptide built almost entirely from D-amino acids that lowers parathyroid hormone in dialysis patients. It is the only drug known to work by forming a reversible disulfide bond with its own receptor — and it does nothing at all in pigs, because pig receptors carry the wrong amino acid at the one position that matters.
Etelcalcetide is an injection given at the dialysis clinic to calm down overactive parathyroid glands, a common problem when kidneys fail. It is a tiny mirror-image peptide that latches onto the calcium sensor on parathyroid cells and makes them act as though blood calcium is higher than it really is, so they stop pumping out hormone. It works better at lowering the hormone than the older daily pill, but nobody has yet shown it helps people live longer or break fewer bones, and it drops blood calcium in most people who take it.
What is Etelcalcetide?
Etelcalcetide is a synthetic peptide given intravenously three times a week at the end of haemodialysis to control secondary hyperparathyroidism — the overactive parathyroid glands that develop in advanced kidney disease. It is sold as Parsabiv and was approved in the European Union in November 2016 and by the FDA in February 2017. Chemically it is unusual twice over. Seven of its eight amino acids are D-amino acids, the mirror images of the L-forms that biology normally uses, which makes the molecule almost invisible to the enzymes that would otherwise chew it up. And the eighth residue is a lone L-cysteine hanging off the chain by a disulfide bond, which is not decoration but the business end of the drug: it swaps onto proteins and onto the receptor itself. The result is a 1,047-dalton peptide with an effective half-life of three to four days, which is why a drug this small can be dosed three times a week instead of continuously.
What Etelcalcetide Is Investigated For
Etelcalcetide's biochemical case is settled and its clinical-outcomes case is not, and the gap between those two things is the honest summary of this drug. Two 26-week placebo-controlled trials enrolling about 1,020 patients established that it lowers PTH, and a 683-patient head-to-head against oral cinacalcet showed it was not merely non-inferior but superior: 68.2% of etelcalcetide patients achieved a greater than 30% PTH reduction against 57.7% on cinacalcet, and 52.4% versus 40.2% achieved a greater than 50% reduction. Real-world data agree — US dialysis facilities that switched from cinacalcet to etelcalcetide saw mean PTH fall from 671 to 484 pg/mL while facilities that stayed on cinacalcet drifted upward from 632 to 698. What none of this establishes is that any patient lives longer, breaks fewer bones, or avoids a cardiovascular event. The surrogate markers that would support such a case have moved in encouraging directions — FGF23 falls, left ventricular mass index progresses more slowly than on alfacalcidol, bone mineral density and trabecular bone score improve over 36 weeks — but no trial has been designed or powered to test hard outcomes, and the cautionary precedent sits close by: EVOLVE, the large cardiovascular outcomes trial of the oral calcimimetic cinacalcet, missed its primary endpoint. A 2025 narrative review covering eight years of post-approval experience reached exactly this conclusion, and it has not changed since.
History & Discovery
Etelcalcetide came out of KAI Pharmaceuticals, a South San Francisco company founded on the protein-kinase-C research of Daria Mochly-Rosen at Stanford and built around peptide drug design. The compound was known internally as KAI-4169 and received the United States Adopted Name velcalcetide before being renamed. Amgen acquired KAI in 2012 for the programme, and the trace of that acquisition survives in the regulatory record: the sponsor of record for NDA 208325 is still listed in Drugs@FDA as KAI Pharmaceuticals Inc, even though the marketed product is Amgen's. The design brief was specific. Cinacalcet, Amgen's own oral calcimimetic approved in 2004, worked but had two persistent problems — gastrointestinal intolerance that limited dosing, and the adherence burden of a daily tablet in patients already taking many. A calcimimetic that could be pushed into the dialysis circuit by a nurse three times a week would solve both at once, provided it could survive in plasma long enough to work between sessions and act on the receptor from outside the cell. The D-amino-acid backbone addressed the first problem and the free L-cysteine, as it turned out, addressed the second twice over: by anchoring the drug to albumin and by bonding directly to the receptor. The founding pharmacology appeared in 2013. The mechanism was pinned down two years later, when Alexander and colleagues traced a complete lack of effect in pigs to a single naturally occurring amino-acid difference in the pig calcium-sensing receptor. Europe approved Parsabiv in November 2016 and the FDA followed on 7 February 2017. Then came a complication nobody in the lab had designed for: US Medicare payment policy. Calcimimetics had moved from Part D to Part B in January 2018 under a transitional drug add-on payment adjustment, which ran for three years and then ended, folding them into the bundled dialysis payment on 1 January 2021. Prescribing patterns shifted afterwards, and the shift was uneven across racial and ethnic groups — a reminder that for a drug administered exclusively inside dialysis units, the reimbursement architecture is part of the pharmacology of access.
How It Works
Parathyroid cells carry a sensor that reads blood calcium. When calcium is high the sensor tells the gland to stop releasing parathyroid hormone; when calcium is low the gland releases more. In advanced kidney disease this loop goes wrong — the glands enlarge, become less sensitive, and pour out hormone that strips calcium from bone and drives calcium into blood vessels. Etelcalcetide attaches to that sensor and turns up its gain, so the gland behaves as if calcium were higher than it is and shuts hormone production down.
Etelcalcetide is an agonist of the calcium-sensing receptor (CaSR), a class C G-protein-coupled receptor on parathyroid chief cells. Its backbone is seven D-amino acids — D-cysteine, D-alanine, three D-arginines, D-alanine and a C-terminal D-argininamide, N-acetylated at the amino terminus — carrying a single L-cysteine attached to the N-terminal D-cysteine by a disulfide bond. The D-configuration confers near-total resistance to peptidases; the arginine-rich backbone gives the molecule a strong positive charge that directs it to the acidic extracellular domain of the receptor; and the appended L-cysteine is the reactive handle. The binding mechanism is genuinely unusual among approved drugs. Alexander and colleagues showed in 2015 that the peptide's free cysteine forms a disulfide bond with cysteine 482 of the human CaSR, in the extracellular region, and that the extent of that bond formation correlates with the degree of receptor activation. The evidence is close to decisive: etelcalcetide has no pharmacodynamic effect at all in pigs, whose CaSR naturally carries tyrosine rather than cysteine at position 482; substituting serine or tyrosine for Cys482 in the human receptor abolishes activity; and introducing cysteine into the pig receptor confers it. Despite the covalent chemistry, the pharmacology is reversible, because disulfide bonds undergo exchange rather than persisting indefinitely. This is a different site from cinacalcet, which binds within the seven-transmembrane helical bundle, and explains both the additive hypocalcaemia risk when the two are combined and the mandatory washout when switching. The same disulfide-exchange chemistry governs the drug's disposition. In blood, etelcalcetide biotransforms by reversible disulfide exchange with endogenous thiols, predominantly forming conjugates with serum albumin; plasma exposure to these conjugates is roughly five-fold that of the free peptide and tracks it over time. The albumin reservoir is what converts a 1,047-dalton peptide with a terminal half-life measured in hours in rats into a drug with an effective half-life of three to four days in dialysis patients, reaching steady state after seven to eight weeks with three- to four-fold accumulation. It is not metabolised by cytochrome P450 enzymes and is neither a substrate nor an inhibitor of the common transporters. Elimination is renal in people with working kidneys and dialytic in people without: haemodialysis clearance is 7.66 L/hour, and about 60% of a radiolabelled dose is recovered in dialysate. One nuance is worth flagging because the FDA label and the preclinical literature frame it slightly differently. The label describes etelcalcetide as allosterically modulating the receptor and enhancing its activation by extracellular calcium. The original pharmacology paper on AMG 416 reported that it activates the human CaSR both in the presence and in the absence of physiological extracellular calcium — a mechanism the authors described as distinct from cinacalcet's. Both statements can be true of a molecule that binds a different domain, but readers comparing sources should expect the discrepancy.
Evidence Snapshot
Human Clinical Evidence
Strong for the biochemical endpoint, absent for clinical outcomes. Two 26-week randomised, double-blind, placebo-controlled trials (508 and 515 patients) both met their primary endpoint of a greater than 30% PTH reduction. A separate 683-patient randomised double-blind double-dummy trial against oral cinacalcet met non-inferiority and then superiority (68.2% versus 57.7%). Multiple prospective and retrospective real-world cohorts, including a 2,596-patient DOPPS analysis and a 2026 propensity-matched 24-month comparison, agree. No trial has tested fracture, cardiovascular events or mortality.
Animal / Preclinical
Adequate and mechanistically decisive. The 5/6 nephrectomised rat work showed dose-dependent PTH reduction, reduced vascular calcification and attenuated parathyroid hyperplasia. The cross-species cysteine-482 work in pigs established the binding mechanism more cleanly than most receptor-pharmacology programmes manage. More recent rodent work has examined cardiac effects — attenuated pressure-overload hypertrophy, and restored cardiac function in chronic hyperphosphataemia via CaSR–cAMP signalling — which is interesting but far upstream of any clinical claim.
Mechanistic Rationale
Strong and specific. The calcium-sensing receptor is a validated target with an approved predecessor (cinacalcet), the binding site on the receptor has been mapped to a single residue, and the disulfide-exchange chemistry explains both the pharmacodynamics and the unusually long effective half-life of a small peptide. The weak link is not the mechanism but the assumption that lowering PTH translates into patient benefit, which the EVOLVE result for cinacalcet left unresolved for the whole class.
Research Gaps & Open Questions
What the current literature has not yet settled about Etelcalcetide:
- 01Whether lowering PTH with etelcalcetide prevents fractures, cardiovascular events or death. Nine years after approval this remains untested, and the comparison case is discouraging: EVOLVE, the only large cardiovascular outcomes trial of a calcimimetic, missed its primary endpoint with oral cinacalcet.
- 02Whether the reduced bone formation rate seen on biopsy is the intended normalisation of high turnover or the first step toward adynamic bone. The 36-week study found density and trabecular score improving while turnover fell, which is reassuring at that timescale, but the label separately warns about adynamic bone with chronic PTH over-suppression and nobody has followed the skeleton for years.
- 03Why roughly a quarter of patients stop within twelve months. The DOPPS analysis that established the figure explicitly could not capture reasons, dose holds or facility protocols, so hypocalcaemia, cost pressure, transplantation and parathyroidectomy are all indistinguishable in the data.
- 04How etelcalcetide compares with the newer Japanese calcimimetics evocalcet and upacicalcet. Switching studies exist but no adequately powered head-to-head, and the comparison matters most for patients who tolerate neither etelcalcetide nor cinacalcet.
- 05Whether the cardiac findings are real. Reduced left ventricular mass index progression against alfacalcidol, slowed left atrial volume index progression, and rodent work showing attenuated pressure-overload hypertrophy and restored cardiac function in hyperphosphataemia all point the same way — but the human data are from one 62-patient trial and its post hoc analyses, with an active comparator rather than placebo.
- 06Whether the pharmacovigilance signals for sepsis, aspiration pneumonia and cerebral haemorrhage reflect the drug or the population. Haemodialysis patients have high background rates of all three, and disproportionality analysis of spontaneous reports cannot separate the two.
- 07Whether a patient-administered calcimimetic of this class is possible at all. The injectable route solved an adherence problem by removing the patient from the equation, which also means the benefit disappears for anyone not on in-centre haemodialysis — including the growing home-dialysis population.
Forms & Administration
Intravenous bolus injection only, given by a healthcare professional into the venous line of the dialysis circuit at the end of each haemodialysis session — three times a week, matched to the dialysis schedule. It is supplied as a ready-to-use preservative-free solution at 5 mg/mL in single-dose vials of 2.5 mg, 5 mg and 10 mg, and must not be mixed or diluted. After injection into the dialysis tubing a sufficient volume of saline must follow, roughly 150 mL of rinse-back; if given after rinse-back, at least 10 mL of saline flush. There is no subcutaneous, oral or home-administration form, and none is in development — the delivery route is the point of the drug. Missed doses are not made up: if a dialysis session is missed, the next scheduled dose is given as prescribed, and if more than two weeks lapse the drug is restarted at 5 mg (or 2.5 mg if that was the last dose).
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Starting dose 5 mg by intravenous bolus three times per week. Maintenance is individualised by titration within a 2.5 to 15 mg range, three times per week. In the pivotal trials the average dose at efficacy assessment was 7.2 mg, scaling with baseline severity — 5.7 mg for patients with screening PTH below 600 pg/mL, 7.4 mg for 600 to 1,000, and 8.7 mg above 1,000.
Frequency
Three times weekly, administered at the end of each haemodialysis session.
Timing Considerations
Time of day
At the end of each haemodialysis session, three times weekly
Relative to meals
No relationship to food — the intravenous route bypasses the gut entirely
Relative to exercise
Not tied to exercise timing.
The timing is not pharmacological preference but a requirement: the drug is injected into the dialysis circuit during or after rinse-back, and haemodialysis is also its main route of elimination in these patients.
Cycle Length
Indefinite. Secondary hyperparathyroidism persists as long as kidney failure does, and PTH rebounds when the drug is stopped. There is no cycling concept here; the only reasons to stop are over-suppression of PTH, persistent hypocalcaemia, parathyroidectomy or kidney transplantation.
Protocol Notes
This is a clinic-administered drug and the dosing practicalities belong to the dialysis unit, not the patient. It goes in as an intravenous bolus into the venous line of the dialysis circuit during rinse-back, followed by roughly 150 mL of rinse-back volume, or intravenously after rinse-back followed by at least 10 mL of saline flush. It must not be mixed or diluted. The titration rhythm is set by calcium rather than by PTH. Corrected serum calcium must be at or above the lower limit of normal before any initiation, dose increase or re-initiation; it is checked one week after any change and every four weeks on maintenance, while PTH is checked four weeks after a change. Increases come in 2.5 mg or 5 mg steps no more often than every four weeks, to a ceiling of 15 mg. If corrected calcium falls below the lower limit of normal but stays at or above 7.5 mg/dL without symptoms, the options are to reduce the dose, pause it, or raise calcium with supplementation, calcium-containing phosphate binders, vitamin D sterols or a higher dialysate calcium concentration. Below 7.5 mg/dL, or with any symptoms, the drug is stopped and the hypocalcaemia treated. Missed doses are not made up. If a dialysis session is missed, the next scheduled dose is given as prescribed. If doses lapse for more than two weeks, treatment restarts at 5 mg — or at 2.5 mg if that was the last dose taken. Switching from cinacalcet requires stopping the tablet at least seven days before the first etelcalcetide injection, because the two bind different sites on the same receptor and the hypocalcaemic effects add.
Etelcalcetide is a prescription-only hospital and dialysis-unit product administered by healthcare professionals into a dialysis circuit. It has no home, subcutaneous or oral form, and has not been studied in parathyroid carcinoma, primary hyperparathyroidism or chronic kidney disease without haemodialysis. The figures above describe approved practice and are not guidance for anyone to act on independently.
Timeline of Effects
Onset
PTH begins falling within hours of the first dose and the change is measurable at the first scheduled check. The label's monitoring schedule reflects this, with corrected serum calcium checked within one week of initiation and PTH assessed at four weeks. Calcium typically moves before the clinical picture does, which is why the early checks are calcium checks: in the pooled trials the proportion of patients recording a decrease in blood calcium reached 64%, and most of that happens early.
Peak Effect
Pharmacokinetic steady state takes seven to eight weeks, with three- to four-fold accumulation driven by the albumin reservoir, so the drug's full effect at a given dose is not visible for close to two months. Clinically the picture takes longer still, because titration runs in four-week steps to a maximum of 15 mg; the pivotal trials assessed efficacy over weeks 20 to 27 for exactly this reason. Skeletal changes lag further — the 36-week bone-quality study found density and trabecular score still improving at the end of follow-up.
After Discontinuation
PTH rises again. Etelcalcetide suppresses secretion while it occupies the receptor and does not shrink or cure the hyperplastic parathyroid glands that drive the disease, so stopping returns the gland to its pre-treatment behaviour over subsequent weeks as the albumin-bound reservoir clears. Serum calcium recovers in the same window, which is usually welcome. The exceptions to this pattern are the two things that genuinely end the disease: parathyroidectomy, and a successful kidney transplant — and even transplantation does not always resolve it, which is why registries track parathyroidectomy rates after transplant in former calcimimetic users.
Monitoring & Measurement
Bloodwork & Labs
- •Corrected serum calcium — the single most important measurement, taken before initiation, one week after any initiation or dose change, and every four weeks on maintenance
- •Intact parathyroid hormone (iPTH) — measured four weeks after initiation or any dose change, then per clinical practice; the trials targeted 300 pg/mL or below and suspended dosing when two consecutive values fell under 100
- •Serum phosphate — falls alongside PTH, and the label records hypophosphataemia in 18% of treated patients
- •Serum albumin — needed to calculate corrected calcium, and separately relevant because albumin is the drug's own carrier
- •Serum magnesium and potassium, as part of routine dialysis monitoring; hyperkalaemia was reported slightly more often on treatment
- •Alkaline phosphatase, as a crude index of bone turnover when PTH is being driven down over long periods
Functional & Performance Tests
- •ECG with QTc measurement in anyone with congenital long QT syndrome, prior QT prolongation, a family history of long QT or sudden cardiac death, or on other QT-prolonging drugs — hypocalcaemia is the mechanism of concern
- •Dual-energy X-ray absorptiometry and trabecular bone score, where the 36-week study found measurable change; neither is routine in dialysis care
- •Echocardiography or cardiac MRI for left ventricular mass index, used as the endpoint in the randomised imaging work but not standard practice
- •Clinical assessment for symptoms of hypocalcaemia — paraesthesias, muscle spasms, cramping — which patients should be taught to report
When to Test
Baseline corrected serum calcium before the first dose, repeated within one week of initiation or any dose adjustment and every four weeks during maintenance. PTH four weeks after initiation or any adjustment. Dose increases no more often than every four weeks. In the pivotal trials the efficacy assessment window was weeks 20 to 27, which is a reasonable guide to when a stable picture emerges.
Interpretation & Notes
Two things make these numbers easier to read. The first is that corrected serum calcium, not ionised calcium, is what the label's thresholds refer to — the 8.3 and 7.5 mg/dL decision points are albumin-corrected total calcium, and a small study has looked at whether point-of-care ionometers can stand in, but the label's arithmetic has not changed. The second is that PTH assays are not interchangeable between laboratories, so a value is only comparable with other values from the same assay; this is a long-standing problem in dialysis care rather than anything specific to this drug. It is also worth separating what the monitoring is for. The calcium checks are safety monitoring, and they are frequent because the drug reliably lowers calcium in most people who take it. The PTH checks are efficacy monitoring, and they drive titration. Neither tells you whether the patient is better off in any way they would notice, because no measurement in routine use does — the outcomes that would answer that question have never been studied.
Common Questions
How is it different from cinacalcet, the pill?
Three ways, and only one of them is pharmacology. First, the route: etelcalcetide is injected into the dialysis circuit by a nurse three times a week, so there is nothing for the patient to remember, while cinacalcet is a daily tablet in people who frequently take a dozen other ones. Second, the receptor site: cinacalcet is a positive allosteric modulator that binds inside the seven-transmembrane bundle of the calcium-sensing receptor, whereas etelcalcetide binds the extracellular portion and forms a disulfide bond with cysteine 482 — a different site entirely, which is why giving both together risks dangerous hypocalcaemia and why the label requires a seven-day washout when switching. Third, tolerability: cinacalcet's nausea and vomiting are dose-limiting for many patients, and the IV route bypasses the gut. Worth noting that the pivotal head-to-head was a double-dummy design, meaning the cinacalcet arm also received supervised daily dosing in a trial setting — so that trial measured pharmacology, not the adherence advantage that was the main argument for building an injectable in the first place.
Why does it not work in pigs?
Because of a single amino acid, and the finding is the cleanest mechanistic evidence this drug has. Etelcalcetide showed a complete absence of pharmacodynamic effect in pigs, which was traced to a naturally occurring difference in the pig calcium-sensing receptor: where the human receptor has cysteine at position 482, the pig receptor has tyrosine. Replacing human Cys482 with serine or tyrosine abolished the drug's activity, and putting cysteine back into the pig receptor restored it completely. Mass spectrometry confirmed a direct disulfide bond forms between the peptide's free cysteine and receptor Cys482, and the extent of bond formation tracked the extent of receptor activation. So the drug is covalent in chemistry but reversible in pharmacology — disulfide bonds exchange, which is why the effect wears off.
How common is low calcium on this drug?
Common enough that it defines the monitoring schedule. In the pooled placebo-controlled trials, 64% of etelcalcetide patients had a decrease in blood calcium recorded as an adverse reaction versus 10% on placebo, and 79% had at least one corrected serum calcium below 8.3 mg/dL versus 19%. Symptomatic hypocalcaemia occurred in 7% versus 0.2%. Severe hypocalcaemia can cause paraesthesias, muscle spasms, seizures, QT prolongation and ventricular arrhythmia, and more etelcalcetide patients had a predialysis QTcF above 500 msec (4.8% versus 1.9%). The label requires calcium to be at or above the lower limit of normal before each initiation or dose increase, measured again within a week, and every four weeks thereafter. Most of this is managed with calcium supplementation, calcium-containing binders, vitamin D sterols or a higher dialysate calcium rather than by stopping the drug.
Do people stay on it?
Often not, and the reasons are only partly clinical. In the US Dialysis Outcomes and Practice Patterns Study cohort of 2,596 new users, discontinuation was 9% by three months, 17% by six and 27% by twelve — and the dataset could not capture why. Uptake was also modest: by August 2019, two and a half years after launch, etelcalcetide had reached 6% of US haemodialysis patients. Then payment policy intervened. Calcimimetics were paid for separately under a Medicare transitional add-on from 2018 through 2020 and folded into the bundled dialysis payment on 1 January 2021, after which etelcalcetide use fell and many patients moved to cinacalcet. A 2026 analysis in the American Journal of Kidney Diseases found those reductions were not evenly distributed across racial and ethnic groups.
Is it used outside dialysis?
No, and the label says so explicitly. Etelcalcetide has not been studied in parathyroid carcinoma, in primary hyperparathyroidism, or in chronic kidney disease patients not on haemodialysis, and is not recommended in any of them. The restriction is partly practical and partly pharmacokinetic: the drug is given into the dialysis circuit at the end of a session, and haemodialysis is itself the main route of elimination — about 60% of a radiolabelled dose is recovered in dialysate. In someone with working kidneys the drug clears renally instead, and none of the dosing work was done in that setting.
Who Etelcalcetide Is NOT For
- •Known hypersensitivity to etelcalcetide or any of its excipients — the only absolute contraindication on the label. Hypersensitivity reactions including facial oedema and anaphylaxis have occurred.
- •Corrected serum calcium below the lower limit of normal at the time of initiation, dose increase or re-initiation. This is a hard stop in the dosing instructions, not a relative caution.
- •Concurrent oral cinacalcet or any other calcium-sensing receptor agonist, which can cause severe, life-threatening hypocalcaemia; cinacalcet must be stopped at least seven days before starting.
- •Chronic kidney disease without haemodialysis, primary hyperparathyroidism and parathyroid carcinoma — not contraindications in the formal sense but explicit limitations of use, because the drug has never been studied in them and is eliminated by dialysis in the population it was designed for.
- •Children and adolescents — safety and effectiveness have not been established in patients under 18.
- •Pregnancy and breastfeeding, where there are no adequate human data.
Drug & Supplement Interactions
Etelcalcetide has an unusually clean pharmacokinetic interaction profile and one serious pharmacodynamic one. On the kinetic side there is almost nothing to say: it is not metabolised by cytochrome P450 enzymes, neither inhibits nor induces them, is not a substrate of P-glycoprotein, BCRP, OAT1/3, OATP1B1/1B3, OCT2 or the peptide transporters, and does not inhibit them either, including the bile salt export pump. A peptide cleared by disulfide exchange onto albumin and then by dialysis simply does not meet the usual machinery of drug interaction. The pharmacodynamic interactions are where the risk lives, and they all run through serum calcium. Combining etelcalcetide with cinacalcet is the clearest hazard — two calcimimetics binding different sites on the same receptor produce additive suppression and can cause life-threatening hypocalcaemia, which is why a seven-day cinacalcet washout is mandatory. Any other agent that lowers serum calcium compounds the same risk and warrants closer monitoring. Running the other way, the drugs used to manage the hypocalcaemia — calcium supplements, calcium-containing phosphate binders, active vitamin D sterols and increases in dialysate calcium concentration — are effectively co-therapy rather than interactions, and the DOPPS cohort showed exactly that pattern in practice, with active vitamin D use rising from 77% to 87% and calcium-based binder use from 41% to 50% in the year after starting etelcalcetide. Two indirect considerations are worth holding. Drugs that prolong the QT interval become more dangerous in a patient whose calcium is being deliberately lowered, since hypocalcaemia prolongs QT on its own and more etelcalcetide patients reached a predialysis QTcF above 500 msec than placebo patients did. And anything that raises the risk of upper gastrointestinal bleeding sits alongside a labelled warning for the same event.
Safety Profile
Common Side Effects
Cautions
- • Hypocalcaemia is the central hazard and can be severe. The label mandates a corrected serum calcium at or above the lower limit of normal before initiation, dose increase or re-initiation, a check within one week, and checks every four weeks on maintenance.
- • Patients with congenital long QT syndrome, prior QT prolongation, a family history of long QT or sudden cardiac death, or any other predisposition to ventricular arrhythmia are at higher risk if calcium falls, and need closer monitoring.
- • A history of seizures matters for the same reason — falling calcium lowers the seizure threshold.
- • Giving etelcalcetide with cinacalcet or any other calcium-lowering agent can produce life-threatening hypocalcaemia. Cinacalcet must be stopped at least seven days before starting etelcalcetide.
- • Hypotension, congestive heart failure and reduced myocardial performance have been reported, and hospitalisation for heart failure was numerically higher than placebo (2% versus 1%); causality has not been established but monitoring is advised.
- • Upper gastrointestinal bleeding has been reported and patients with existing risk factors may be at greater risk.
- • Chronically over-suppressed PTH can produce adynamic bone disease, in which bone stops turning over at all; the label instructs reducing or stopping the drug if PTH falls below target.
- • A 2025 pharmacovigilance analysis of 2,525 FAERS reports flagged a peak in adverse-event reporting within the first 30 days and disproportionality signals for sepsis, aspiration pneumonia, cerebral haemorrhage and bile duct stones. Spontaneous-report data cannot establish causation in a population this sick, but the early-treatment clustering is consistent with the trial data.
What We Don't Know
Whether lowering PTH with this drug changes anything a patient would notice. The entire evidence base rests on biochemical endpoints and imaging surrogates, and the one large cardiovascular outcomes trial ever run in this class — EVOLVE, using oral cinacalcet — missed its primary endpoint. Fracture rates, cardiovascular events and mortality have never been tested for etelcalcetide and probably never will be, because the trial would need to be very large and very long. Also unresolved: how the drug compares with the newer Japanese calcimimetics evocalcet and upacicalcet, whether the bone-turnover suppression seen on biopsy is a benefit or an early step toward adynamic bone, and what accounts for the quarter of patients who stop within a year.
Legal Status
United States
FDA-approved and marketed. Parsabiv was approved on 7 February 2017 under NDA 208325 for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis, and remains listed as a prescription product in three single-dose vial strengths. It is not a controlled substance. The label carries explicit limitations of use against parathyroid carcinoma, primary hyperparathyroidism and non-dialysis CKD. Because it is administered inside dialysis facilities, US access is shaped by Medicare's end-stage renal disease payment system: calcimimetics were paid under a transitional drug add-on from January 2018 through December 2020 and have been inside the bundled payment since 1 January 2021.
International
Authorised in the European Union since 11 November 2016, with Amgen Europe B.V. as marketing-authorisation holder, for secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis. Approved in Japan and numerous other markets. Japan is also the one place with a crowded calcimimetic field — evocalcet and upacicalcet were developed and approved there, and Japanese switching studies between agents have no counterpart elsewhere.
Sports & Competition
Not prohibited, and not plausibly relevant. Etelcalcetide appears nowhere on the WADA 2027 Prohibited List, no class covers calcimimetics or calcium-sensing receptor agonists, and the drug has no performance rationale — it lowers parathyroid hormone and serum calcium in people on dialysis. The only incidental consideration is that it is given intravenously inside a dialysis circuit, and prohibited method M2.2 caps intravenous infusions or injections at 100 mL per 12 hours except where legitimately received during hospital treatment; dialysis is exactly such a treatment, and an athlete on maintenance haemodialysis would be documenting that anyway.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Etelcalcetide is just injectable cinacalcet.
Reality
They activate the same receptor at different sites by different chemistry. Cinacalcet is a small molecule that binds within the seven-transmembrane helical bundle and acts as a positive allosteric modulator; etelcalcetide is a D-amino-acid peptide that binds the extracellular region and forms a reversible disulfide bond with cysteine 482. The practical proof that these are not the same drug is the mandatory seven-day washout when switching, which exists precisely because their effects on calcium are additive.
Myth
The head-to-head trial proved the IV route improves adherence.
Reality
It could not have, by design. The pivotal 683-patient comparison was double-blind and double-dummy, meaning the cinacalcet arm received both their oral drug and an IV placebo, and the etelcalcetide arm an oral placebo — all under trial supervision. That design isolates pharmacology, which is what it was meant to do, but it removes the real-world adherence gap entirely. The evidence that the route matters in practice comes from observational work instead, such as the facility-level analysis showing PTH falling where units switched and rising where they did not.
Myth
Low calcium is an occasional side effect.
Reality
It is the expected pharmacology. Seventy-nine percent of patients in the pooled placebo-controlled trials recorded at least one corrected serum calcium below 8.3 mg/dL, against 19% on placebo; 27% went below 7.5 mg/dL. The drug makes the parathyroid gland behave as though calcium is high, so calcium falls — that is the mechanism working, not failing. What distinguishes a well-run course from a dangerous one is whether the monitoring schedule and the calcium and vitamin D co-therapy keep pace with it.
Myth
It is a bone drug.
Reality
It is a parathyroid drug whose skeletal effects are downstream and not fully characterised. The one direct bone study, a 36-week single-arm trial, found improvements in areal bone mineral density and trabecular bone score alongside a fall in bone formation rate — but it enrolled 22 people, 13 completed, and 5 had biopsies. No fracture data exist. Teriparatide, abaloparatide and calcitonin are drugs whose indication is the skeleton; etelcalcetide's is a hormone level.
Myth
Peptides are too fragile to survive in the bloodstream for days.
Reality
Not when they are built from the wrong-handed amino acids and attached to albumin. Etelcalcetide's seven D-residues make it a poor substrate for peptidases, and its free L-cysteine performs disulfide exchange onto serum albumin, producing conjugates whose plasma exposure runs about five-fold that of the free peptide. Together these turn a 1,047-dalton molecule into a drug with a three- to four-day effective half-life — long enough for a thrice-weekly schedule with no infusion pump.
Published Research
35 studiesReal-World Etelcalcetide Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients with Inadequate Cinacalcet Response or Intolerance
Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up
Öztürk H et al., J Clin Med 2026. Propensity-matched cohorts across five Turkish centres extending the comparison past the one-year mark that trials stop at. Sustained response was 78.6% versus 28.6% for cinacalcet and inter-patient variability was nearly three-fold lower on etelcalcetide. The caveat is size: matching left 21 versus 21 patients at twelve months and 14 versus 14 at twenty-four.
Racial and Ethnic Variations in Reductions in Etelcalcetide Use After Withdrawal of the Transitional Drug Add-on Payment Adjustment
Caldwell JS et al., AJKD 2026. Calcimimetics were paid separately under a Medicare transitional add-on from 2018 through 2020 and moved into the bundled dialysis payment on 1 January 2021. Etelcalcetide use fell afterwards — and this analysis found the reductions differed by race and ethnicity, which makes a reimbursement mechanism an access question rather than an accounting one.
Calcimimetics and CaSR signaling in CKD-MBD: bone-immune-vascular crosstalk and therapeutic potential
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective
Tran L et al., Drug Development Research 2026. Useful context for why etelcalcetide's chemistry is unusual: D-amino acids remain rare in approved drugs, and the handful that use them do so for the same reason — mirror-image residues are poor substrates for the proteases that destroy ordinary peptides.
Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy
The effects of switching from etelcalcetide to upacicalcet in hemodialysis patients with secondary hyperparathyroidism
Real-world safety profile of etelcalcetide in dialysis-related secondary hyperparathyroidism: a pharmacovigilance analysis of FAERS data
Zou C et al., Renal Failure 2025. Disproportionality analysis of 2,525 FAERS reports from 2017–2024. Hypocalcaemia, gastrointestinal and cardiovascular events dominated, 23.45% of events clustered in the first 30 days, and new signals appeared for sepsis, aspiration pneumonia, cerebral haemorrhage and bile duct stones. Spontaneous reports cannot establish causation in a population with this much background illness, but the early-treatment clustering matches the trial data.
The calcium-sensing receptor: a comprehensive review on its role in calcium homeostasis and therapeutic implications
Adverse events reporting of Etelcalcetide: a real-word analysis from FAERS database
Etelcalcetide: What we know eight years since its approval
Freitas P and Pereira L, Nefrologia 2025. A narrative review that lands on the central honest point: etelcalcetide reliably reduces PTH, calcium, phosphate and FGF23, and the bone and cardiovascular surrogates look encouraging, but there is a lack of studies specifically designed to evaluate its role in reducing fractures, cardiovascular events or all-cause mortality.
Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina
Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation
New Insights into the Effects of Etelcalcetide on Bone Health
Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients
Dörr K et al., Cardiorenal Medicine 2023. A post hoc cardiac-MRI analysis of the 62-patient EtECAR-HD trial, which had randomised etelcalcetide against alfacalcidol for a year. Left atrial volume index is a recognised risk marker in dialysis, and this is one of the few randomised cardiac-imaging datasets for the drug — but it is a post hoc endpoint in a small trial, not an outcomes result.
Changes in Bone Quality after Treatment with Etelcalcetide
Khairallah P et al., CJASN 2023. A single-arm 36-week trial in which only 13 of 22 enrolled participants completed follow-up and 5 had bone biopsies — small, but the first direct look at the skeleton. PTH fell 67%, areal bone mineral density rose 3–7% at spine, femoral neck and total hip, trabecular bone score rose 10%, and biopsy showed reduced bone formation rate without deterioration in bone material properties.
Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life study
Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet
Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis
Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease
Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness
Karaboyas A et al., Kidney Medicine 2022. A clever design that sidesteps patient-level confounding by classifying whole dialysis facilities as etelcalcetide-first or cinacalcet-first. Facilities that switched saw mean PTH fall from 671 to 484 pg/mL while facilities that stayed on cinacalcet rose from 632 to 698, a difference-in-difference of −169 pg/mL.
Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients
Karaboyas A et al., AJKD 2022. A DOPPS new-user analysis of 2,596 US patients. Mean PTH fell 40% over twelve months (948 to 566 pg/mL) and the proportion within the 150–599 pg/mL target rose from 33% to 64%. The less-quoted numbers are the discontinuation curve — 9%, 17% and 27% by three, six and twelve months — and the uptake: by August 2019 etelcalcetide had reached 6% of US haemodialysis patients.
Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials
Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life"
Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial
Block GA et al., JAMA 2017. The pivotal head-to-head: 683 haemodialysis patients with PTH above 500 pg/mL randomised to IV etelcalcetide plus oral placebo or oral cinacalcet plus IV placebo for 26 weeks. Etelcalcetide met non-inferiority and then superiority — 68.2% versus 57.7% achieved a greater than 30% PTH reduction, and 52.4% versus 40.2% a greater than 50% reduction. Decreased blood calcium was more common on etelcalcetide (68.9% versus 59.8%). The double-dummy design is worth noting: both arms received supervised dosing, so the trial compared pharmacology rather than the real-world adherence advantage that motivated an injectable calcimimetic.
Etelcalcetide: First Global Approval
Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action
Alexander ST et al., Molecular Pharmacology 2015. Established that etelcalcetide forms a disulfide bond with cysteine 482 in the extracellular domain of the human calcium-sensing receptor, with the extent of bond formation correlating with receptor activation. The decisive evidence came from a species difference: the drug is pharmacodynamically inert in pigs, whose receptor carries tyrosine at position 482, and introducing cysteine restored full activity. Despite the covalent bond, the in vivo pharmacology is reversible.
Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients
Walter S et al., JPET 2013. The founding pharmacology paper from KAI Pharmaceuticals and Amgen. Reported that the peptide activates the human CaSR in both the presence and the absence of physiological extracellular calcium — a mechanism the authors describe as distinct from cinacalcet's — and that treating 5/6 nephrectomised rats lowered PTH and creatinine, reduced vascular calcification and attenuated parathyroid hyperplasia.
PARSABIV (etelcalcetide) injection — US Prescribing Information
Quick Facts
- Class
- Calcium-Sensing Receptor Agonist (Calcimimetic)
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Oct 2026
- Citations
- 35PubMed
Also known as
Tags
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.